HOME - LATEST NEWS - Corporate - LT3001 Received IND Approval from China's NMPA





LT3001 Received IND Approval from China's NMPA

Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its China partner Shanghai Pharmaceutical Holding (SHP) has received the IND approval from China’s NMPA for the lead drug candidate, LT3001,  a novel treatment for acute ischemic stroke.  A phase 2 clinical study is currently on-going in the US and Taiwan. Once China studies are initiated, the clinical trials from Chinese sites will contribute additional data to accelerate LT3001 towards market approval.


LT3001 is a novel small molecule entity indicated for the treatment of acute ischemic stroke. Animal studies have demonstrated LT3001 possessing multiple functions in restoring cerebral blood flow and reducing reperfusion injury.


Stroke is the #1 cause of death and disability in China. Besides of its high mortality rate, the disease also has high incidence, recurrence and disability rates, with more than 10 million patients.